title: Developments in HIV-1 immunotherapy and therapeutic vaccination.
abstract: Since the human immunodeficiency virus (HIV-1) pandemic began, few prophylactic vaccines have reached phase III trials. Only one has shown partial efficacy in preventing HIV-1 infection. The introduction of antiretroviral therapy (ART) has had considerable success in controlling infection and reducing transmission but in so doing has changed the nature of HIV-1 infection for those with access to ART. Access, compliance, and toxicity alongside the emergence of serious non-AIDS morbidity and the sometimes poor immune reconstitution in ART-treated patients have emphasized the need for additional therapies. Such therapy is intended to contribute to control of HIV-1 infection, permit structured treatment interruptions, or even establish a functional cure of permanently suppressed and controlled infection. Both immunotherapy and therapeutic vaccination have the potential to reach these goals. In this review, the latest developments in immunotherapy and therapeutic vaccination are discussed.
authors.affiliation: St George's, University of London, Institute for Infection and Immunity 1 Cranmer Terrace, London SW17 0RE UK.
authors.forename: Peter Lawrence
authors.initials: PL
authors.lastname: Smith
authors.affiliation: St George's, University of London, Institute for Infection and Immunity 1 Cranmer Terrace, London SW17 0RE UK.
authors.forename: Helen
authors.initials: H
authors.lastname: Tanner
authors.affiliation: St George's, University of London, Institute for Infection and Immunity 1 Cranmer Terrace, London SW17 0RE UK.
authors.forename: Angus
authors.initials: A
authors.lastname: Dalgleish